Trial Profile
Safety and efficacy of transdermal rotigotine for the treatment of fatigue and quality of life (QOL) in patients with Parkinson's disease.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Aug 2015
Price :
$35
*
At a glance
- Drugs Rotigotine (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- 13 Aug 2015 New trial record
- 18 Jun 2015 Results presented at the 19th International Congress of Parkinson's Disease and Movement Disorders.